Comera Life Sciences Holdings, Inc. CMRA
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 81.82% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 81.82% | -- | -- | -- | -- |
| Cost of Revenue | 33.18% | -- | -- | -- | -- |
| Gross Profit | 109.31% | -- | -- | -- | -- |
| SG&A Expenses | -27.21% | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.04% | -- | -- | -- | -- |
| Operating Income | 30.39% | -- | -- | -- | -- |
| Income Before Tax | 47.21% | -- | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 47.21% | -- | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.21% | -- | -- | -- | -- |
| EBIT | 30.39% | -- | -- | -- | -- |
| EBITDA | 30.70% | -- | -- | -- | -- |
| EPS Basic | 96.99% | -- | -- | -- | -- |
| Normalized Basic EPS | 97.65% | -- | -- | -- | -- |
| EPS Diluted | 96.99% | -- | -- | -- | -- |
| Normalized Diluted EPS | 97.65% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 211.11% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 211.11% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |